-
Product Insights
Glomerulonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Glomerulonephritis - Drugs In Development, 2023’, provides an overview of the Glomerulonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Thematic Analysis
State of the Biopharmaceutical Industry in 2024 – Thematic Intelligence
Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you in: Examining the current attitudes of business leaders toward the emerging trends impacting the biopharmaceutical industry in the next 12 months. Benchmarking the impact of major themes on the biopharmaceutical industry in 2024, including emerging technologies, regulatory trends, macroeconomic trends, and industry trends. Identifying the most impactful anticipated regulatory approvals and drug launches in the industry in 2024, learning about top-selling drugs (2023 vs 2024), and obtaining...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ISM-001 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ISM-001 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ISM-001 in Idiopathic Pulmonary Fibrosis Drug Details:ISM-001055 is under development for the...
-
Product Insights
Cardiac Marker Tests Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Cardiac Marker Tests Pipeline Market Overview A cardiac marker test is a biomarker test used to diagnose cardiac diseases. The Cardiac Marker Tests pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Other Cardiac Marker...
-
Thematic Analysis
Digital Transformation and Emerging Technologies in the Healthcare Industry – Thematic Intelligence
Explore trends and insights from the following data in our ‘Digital Transformation and Emerging Technologies in the Healthcare Industry’ report: Stay up to date on the scope, challenges, and essentials for the digital transformation within the healthcare industry. Explore how innovations are transforming the healthcare industry and what impact on the sector these technologies will have soon. Develop and design your corporate strategies through an in-house expert analysis of the key factors of digital transformation and emerging technology in the healthcare sector....
-
Sector Analysis
Artificial Intelligence in Pharma – Impact, Trends, Key Players and Top AI Drugs
This report investigates the impacts and development of Artificial Intelligence within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.
-
Company Insights
Boehringer Ingelheim – Digital Transformation Strategies
Boehringer Digital Transformation Strategies Report Overview Boehringer Ingelheim (Boehringer) is tapping into key disruptive technologies including AI, big data, digital therapeutics, and cloud, among others to enhance its operational efficiency and product offerings. The annual ICT spending of Boehringer is estimated at $1.0 billion for 2022. A major share of this spending is earmarked for acquiring software, ICT services and hardware from vendors. Boehringer is a family-owned pharmaceutical company engaged in the discovery, development, manufacture, and marketing of human pharmaceuticals...
-
Thematic Analysis
Generative Artificial Intelligence (AI) in Defense – Thematic Intelligence
Access and explore in-depth trends and insights in our ‘Generative Artificial Intelligence (AI) in Defense’ report: Explore investment opportunities for armed forces, suppliers, and institutional investors, across the emerging generative AI value chain. Highlights from the range of different generative AI research and development initiatives currently being undertaken by various military organizations and defense companies. Studies of emerging technological trends and their broader impact on the defense market. How is the 'Generative Artificial Intelligence (AI) in Defense' report different from...